pp-078 Injection

Indication: Vocal cord scarring (vocal fold fibrosis) causing impaired phonation and reduced vocal function. Clinical stage: Phase I/II open-label dose-escalation investigator-initiated trial completed; Phase III multicenter, randomized, placebo-controlled, double-blind comparative trial ongoing. Mechanism / Target: the c-MET receptor activation to promote antifibrotic activity, tissue repair, and regeneration within the vocal fold lamina propria, aiming to restore pliability and vocal fold vibration. Route / form: Local intracordal injection into the vocal fold, as used in clinical studies. Differentiation: First-in-class regenerative biologic directly targeting fibrosis and restoring vocal function; demonstrated safety and biological activity in early trials and is advancing through pivotal evaluation.